Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development --- --- John Adams, PhD Appointed Chief ...

Inhibikase Therapeutics (IKT) announced the appointment of two pharma industry executives to its senior leadership team. Chris Cabell, M.D., ...

BOSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today ...

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug ...

BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company with a market capitalization of $201.58 million, has announced the addition of two seasoned executives ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes.

H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused ...

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders ...

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced the appointment of two ...